Spinal cord stimulation

Series
Neuromodulation
Status
Published
Date
Number of report
037

Ask the expert

(we accept only company emails)

The report presents a summary of the reimbursement situation for use of spinal cord stimulation. Indications include neuropathic and ischemic pain.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

Clinical scenarios include trial insertion of electrodes and external stimulator, permanent implantation of spinal cord stimulator, adjustment/programming of stimulator, removal of stimulator, and replacement of battery of pulse generation.

The only reimbursement within public / statutory health insurance systems is considered.

The report includes essential information about reimbursement, including:

  • Brief country-specific overview of reimbursement system
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions on indications or scenarios for the use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • Finland
  • France
  • Germany
  • Italy
  • The Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of the spinal cord stimulation devices include:

  • Boston Scientific (Precision)
  • Nevro (Senza)
  • Stimwave (Freedom SCS)
  • Abbot Vascular (BurstDR: Proclaim, Prodigy MRI IPG, St. Jude Medical Invisible Trial System; Eon)
  • Medtronic (Intellis; SureScan: RestoreSenso, RestoreUltra, RestoreAdvanced, PrimeAdvanced)
  • Saluda Medical (Evoke SCS System)
  • Nuvectra (Algovita SCS)
  • Med-Ally (VersaStim IPG Platform)

Table of content is not available at this moment.

16

Mar 2023

In January-February 2023, Health Technology Wales published sixteen Medtech-related Topic Exploration Reports (TER), including stereotactic radiosurgery, percutaneous implantation of pulmonary artery pressure sensors, ambulatory patch ECG devices, and others; however, Health Technology Wales will not proceed with full appraisals on these topics. No Guidance was released for Medtech in January-February 2023.

Read more

27

Feb 2023

In January and February 2023, Ordering Forum for the “New Methods” framework invited interested parties regarding several technologies proposed for evaluation within the framework. The technologies concern arteriovenous fistula for hemodialysis, deep brain stimulation, epidural spinal cord stimulation, and digital chest drain. Ordering Forum will decide whether the technology undergoes evaluation at the national level.

Read more

03

Feb 2023

On January 30, 2023, the Institute for the Hospital Remuneration System (InEK) published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2022. The medical technologies belonging to the cardiovascular, eHealth, gastrointestinal, neuromodulation, neurovascular, peripheral vascular, orthopedic, and other technology groups obtained positive status 1.

Read more

31

Jan 2023

In January 2023, the National Institute for Health and Care Excellence (NICE) published four new Interventional Procedure Guidance (percutaneous image-guided cryoablation of peripheral neuroma, laparoscopic insertion of a magnetic ring, transcutaneous electrical stimulation of the trigeminal nerve, and trabeculectomy with a biodegradable collagen matrix implant ), two new Diagnostic Guidance (devices for remote monitoring of Parkinson's disease, MRI-based technologies for assessing non-alcoholic fatty liver disease), and three new Medtech Innovation Briefings (PredictSURE IBD, Ambu aScope 4 Broncho, and Aquablation robotic therapy). One MedTech-related clinical guideline was updated.

Read more

13

Jan 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in December 2022. Nine recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern the device used for neuromodulation, the device for the treatment of benign prostatic hyperplasia, orthopedic devices, as well as medical aids.

Read more
(we accept only company emails)